Journal of managed care & specialty pharmacy

Stopping glucagon-like peptide-1 receptor drugs among US adults: results from a national survey

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Reasons for discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remain unclear.

  • Many patients stop using GLP-1 RAs for reasons that have not been thoroughly investigated.
  • Understanding these reasons could help improve adherence to treatment.
  • Identifying factors associated with discontinuation may enhance patient outcomes.

Simplified

Related papers

Oct '25
Healthcare costs and treatment patterns linked to use of diabetes-related medication in patients with fatty liver disease and metabolism problems
top 30% journal
cited by 1 paper
journal article
Sep '25
Usage patterns and expenses of diabetes drugs that activate the GLP-1 receptor in US adults with type 2 diabetes
top 20% journal
cited by 3 papers
journal article
Jan '25
Stopping and Restarting Dual-Action GLP-1 Weight-Loss Medicines in US Adults with Overweight or Obesity
top 2% journal
cited by 203 papers
research support, non-u.s. gov't
Dec '25
Extra healthcare costs linked to diabetes treatment with GLP-1 medicines in US adults
top 20% journal
journal article
Aug '22
Treatment continuation and following instructions in people with type 2 diabetes switching to a combined insulin and medication versus separate insulin and glucagon-like peptide-1 drugs
top 20% journal
cited by 5 papers
journal article
Jun '25
Health care use and costs in Medicare Advantage patients using GLP-1 receptor agonists compared to SGLT-2 inhibitors
top 20% journal
comparative study
Apr '26
Differences between states in using diabetes and weight loss drugs that target GLP-1 receptors
top 20% journal
journal article
Apr '24
Lower effectiveness of GLP-1 receptor agonist treatment in people with type 1 diabetes and inherited obesity
top 10% journal
cited by 8 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief